🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD

RecruitingPhase 2Ages 18 Years - 70 YearsAllUniversity of Haifa
NCT07771530 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Posttraumatic stress disorder (PTSD) is a chronic and often treatment-resistant psychiatric condition that emerges following exposure to trauma and is characterized by intrusive thoughts, emotional dysregulation, and cognitive impairments. In Israel, the prevalence of PTSD has increased significantly in the aftermath of the October 7, 2023 terror attacks, emphasizing the urgent need for more effective, accessible, and personalized interventions. Existing treatments, such as trauma-focused CBT and SSRIs, remain only partially effective, with side effects that reduce adherence and limit long-term recovery. The proposed randomized controlled trial will assess and compare two promising treatment modalities: (i) a new pharmacological combination of reboxetine and methylphenidate, designed to enhance noradrenergic and dopaminergic pathways involved in attention and emotional regulation, and (

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age between 18 and 70 years, * diagnosed with PTSD according to DSM-IV or DSM-5 criteria, * any psychotropic drug therapy that is being administered must be at a fixed dose for at least one month prior to the study initiation. Exclusion Criteria: * any health condition for which the use of reboxetine or methylphenidate is contraindicated, * comorbidity with major psychiatric disorder, * significant/active cardiovascular disease, * previous or current severe traumatic brain injury, * active substance dependency, * participating in another treatment program for PTSD of any kind.
💊

What it tests

  • methylphenidate (Ritalin®)
  • Reboxetine
  • Placebo
  • Placebo
  • Dog-Assisted Therapy
📍

Where

1 site
University of Haifa
Haifa, Israel
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy